Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

David S. Hong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8721-1609; OpenAlex author ID A5026095888. Sources: funder_awards.

Their work

Papers
11 (first author 0, last author 2)
Trials
3 (principal investigator on 3)
Grants
1
Labs led
1
Collaborators
64
Papers, trials and grants by year

2004: 1 grant · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper, 3 trials · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 11

  1. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Co-author DOI 10.1038/s41591-026-04537-w↗
  2. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. Last author DOI 10.1056/nejmoa2505783↗
  3. Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications. Co-author DOI 10.1158/1078-0432.ccr-26-0344↗
  4. Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach. Co-author DOI 10.1002/cam4.71447↗
  5. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  6. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. Co-author DOI 10.1172/jci.insight.169150↗
  7. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Tri… Co-author DOI 10.1007/s12029-023-00930-7↗
  8. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. Last author DOI 10.1056/nejmoa2208470↗
  9. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Co-author DOI 10.18632/oncotarget.19897↗
  10. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.7773↗
  11. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Co-author DOI 10.1002/cncr.25346↗

Trials 3

  1. Study of Ixazomib and Erlotinib in Solid Tumors Principal investigator NCT02942095↗
  2. Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal C… Principal investigator NCT02983578↗
  3. Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Principal investigator NCT03098160↗

Grants 1

  1. Src Kinase Inhibition with BMS-354825 in Pancreatic Cancer Models AWARD pancan:2004-david-s-hong-md-src-kinase-inhibition-with-bms-354825-in

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ignacio Garrido‐Laguna · 3 shared papers, 2023–2026 · strength 0.54
  2. Jordi Ahnert Rodon · 2 shared papers, 2023–2026 · strength 0.42
  3. Shubham Pant · 2 shared papers, 2023–2026 · strength 0.42
  4. Alexander Starodub · 2 shared papers, 2026 · strength 0.41
  5. Wungki Park · 2 shared papers, 2026 · strength 0.41
  6. Brian Matthew Wolpin · 2 shared papers, 2026 · strength 0.41
  7. Minal A. Barve · 2 shared papers, 2026 · strength 0.41
  8. Alexander I. Spira · 2 shared papers, 2026 · strength 0.41
  9. Dan Zhao · 1 shared paper, 2026 · strength 0.26
  10. Camila Bragança Xavier · 1 shared paper, 2026 · strength 0.26
  11. Jennifer Brooke Valerin · 1 shared paper, 2025 · strength 0.25
  12. Farshid Dayyani · 1 shared paper, 2025 · strength 0.25
  13. David K. Imagawa · 1 shared paper, 2025 · strength 0.25
  14. Robert A. Wolff · 3 shared papers, 2011–2023 · strength 0.25
  15. Steven Neema Seyedin · 1 shared paper, 2025 · strength 0.25
  16. Garrett K. Harada · 1 shared paper, 2025 · strength 0.25
  17. Zeljka Jutric · 1 shared paper, 2025 · strength 0.25
  18. Aung Naing · 3 shared papers, 2011–2023 · strength 0.25
  19. David R Piwnica-Worms · 1 shared paper, 2024 · strength 0.23
  20. Akash R. Boda · 1 shared paper, 2024 · strength 0.23
  21. Casey R. Ager · 1 shared paper, 2024 · strength 0.23
  22. Arthur J. Liu · 1 shared paper, 2024 · strength 0.23
  23. Michael A. Curran · 1 shared paper, 2024 · strength 0.23
  24. Joel Randolph Hecht · 1 shared paper, 2026 · strength 0.23
  25. Nilofer Saba Azad · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.